Impact of Gefitinib on First Line Treatment In Non-small-cell Lung Cancer Patients

Objective To evaluate the clinical efficacy and safety of gefitinib in the first line treatment of ormetastatic NSCLC.Methods Twenty-three NSCLC patients were treated with Gefitinib orally 250 mg oncedaily until disease progressi on or the occurrence of intolerablet oxicity,We grouped them into controlled(CR + PR + SD) or unconctrolled(PD),compared their clinical character and difference of clinical efficacy.Results Among these 23 patients,CR 0(0%),PR 12(52.1%),SD 14(60.8%),PD 7(30.4%) 1,the clinical benefit response was 70%.Kaplan-Meier show the NSCLC patients responded to gefitinib had survival benefit than those had no response.COX regression analysis showed that the effecacy of gefitinib was the influence factor of their survival(P 0.01),while gender,age,pathologic type,and smoking history were not influence factors(P 0.05).Conclusion Gefitinib is effective and safe in the first line treatment of patients with ormetastatic NSCLC,which can relieve symptom and improve the quality of the life.